Introduction
Approximately 14.8 million US adults (6.7%) experience major depression in a given year (1) , and women are 1.7 times as likely to experience depression as men (2) . The 12-month prevalence of major depressive disorder, 1 form of clinical depression, for nonpregnant women aged 18 to 50 ranges from 8% to 16% (2, 3) and may be highest among low-income women, for whom prevalence of depression (defined as minor depression/dysthymia or major depression) is estimated at 29% (4) . Yet, only half of women with depression have ever received a clinical diagnosis of the
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Among Nonpregnant Women of Reproductive Age in the United States, 1990 States, -2010 disorder (4) , which is the first step toward treatment and recovery. Major depression is the leading cause of disability in the United States for adults aged 15 to 44 (5) and is associated with diabetes (6), stroke, and coronary heart disease (7). Depression affects a woman's preconception health (8) ; depression during pregnancy may affect pregnancy outcomes, such as preterm delivery and low birth weight (9) (10) (11) and may adversely affect the child's intellectual development, behavior, and mental health (12) . In 1 study among women enrolled in Kaiser Permanente Northwest, approximately half of women with clinically diagnosed perinatal depression experienced depression in the 39 weeks before pregnancy (13) , highlighting the need for identification and treatment of depression among nonpregnant women of reproductive age.
Nonpsychiatric clinicians have difficulty recognizing depression in their patients (14, 15) . One meta-analysis found that nonpsychiatric clinicians accurately diagnosed depression in only 36% of depressed patients; another meta-analysis found a rate of 47% (14, 15) . However, it remains unclear whether routine screening for depression among nonpregnant women of reproductive age, defined as aged 15 to 44 years, improves identification, increases treatment rates, and leads to better overall and preconception health. To consolidate current knowledge in this area, we conducted a systematic review of the literature to address 5 key questions specific to this group of women: 1) What are the current national clinical practice recommendations and guidelines for depression screening; 2) What are the prevalence and predictors of screening; 3) How well do screening tools detect depression; 4) Does screening lead to diagnosis, treatment, and improved outcomes; and 5) What are the most effective treatment methods?
Methods

Data sources
We searched the following electronic bibliographic databases: PubMed/MEDLINE (www.ncbi.nlm.nih.gov/ pubmed/), PsycINFO (www.apa.org/pubs/databases/psycinfo/index.aspx), the Cochrane Database of Systematic Reviews (Cochrane Reviews) (www2.cochrane.org/ reviews/); and the National Guideline Clearinghouse (http://www.guideline.gov/). We used a combination of free-text terms and terms from the National Library of Medicine's Medical Subject Headings (MeSH) (www.nlm. nih.gov/mesh/). We conducted 3 separate searches focused on the following: 1) screening guidelines, 2) screening for depression in nonpregnant women of reproductive age, and 3) treatment for depression. We limited searches to English-language articles published between January 1, 1990, and December 1, 2010, that described studies enrolling human participants. Free-text terms included those related to screening and treatment of depression, population-based surveys, and study types (Appendix). We supplemented searches of bibliographic databases by reviewing reference lists of retrieved articles and by searching reports, studies, articles, and monographs produced by federal and local government agencies, private organizations, and educational organizations. For searches of articles, we used a 2-stage approach. We first searched for systematic reviews, defined as articles that synthesized relevant data from a number of independent studies and included well-defined, comprehensive search strategies, and then for individual studies, defined as research studies involving human subjects that were not meta-analyses or systematic reviews.
Study selection
We developed inclusion criteria for each question a priori (Table 1) . We conducted searches between March and December 2010.
For question 1, we initially identified depression screening guidelines from 190 national organizations. After a review of summaries of the guidelines, we deemed 21 relevant and reviewed them fully. Of these, we excluded 16 because they were not from US-based organizations or because the guidelines did not focus primarily on depression.
For study questions 2 through 5, an initial search of systematic reviews, meta-analyses, and post hoc analyses of pooled data found 5,200 mentions of depression. From this initial search, we categorized these mentions by each study question. We reviewed some studies for more than 1 study question. The reasons for exclusion were that a separate synthesis of women was not reported (n = 186); the study was not a systematic review, meta-analysis or post-hoc analysis of pooled data (n = 43); or the study did not address our study question (n = 105). For questions 2 through 5, the initial searches found 2,337 potential individual studies. We reviewed 334 individual studies and excluded 330 because they did not address our study questions. Therefore, we include a total of 12 systematic reviews, meta-analyses, or post-hoc analyses of pooled data and 4 individual studies that met our inclusion criteria for
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questions 2 through 5. Below, we summarize specific studies included in each key question.
For question 5, we limited nonpharmacotherapy treatments to treatments described by the greatest number of systematic reviews identified: exercise and psychotherapy. We also limited pharmacotherapy to the 2 most common types, selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). For pharmacotherapy, we included only studies published from January 1, 2000, through December 1, 2010, because medications change over time, recent studies are most relevant, and systematic reviews offer a succinct summary measure of effectiveness.
Data extraction
Data extracted from the selected studies included study populations, outcomes and covariates, and results. For all study questions, at least 2 authors reviewed and discussed each article until both authors concurred on its inclusion.
Results
We identified recommendations and guidelines from 5 national groups to answer question 1, and we identified 16 studies that met our final review criteria for questions 2 through 5. For question 2, we found 4 individual studies; for question 3, 1 meta-analysis; for question 4, 2 metaanalyses and 1 systematic review; and for question 5, 5 meta-analyses and 3 post-hoc analyses of pooled data.
Question 1. What are the current national clinical practice recommendations and guidelines for depression screening?
We identified recommendations and guidelines from 5 national groups for screening adults for depression (16) (17) (18) (19) (20) ; however, none provided specific guidance for nonpregnant women of reproductive age ( Table 2 ). The US Preventive Services Task Force (USPSTF) recommends that providers screen adults for depression only when staff-assisted depression care supports are in place to ensure accurate diagnosis, effective treatment, and follow-up (17) . The USPSTF defines "staff-assisted care supports" as clinical staff who assist the primary care clinician by providing some direct depression care or coordination, case management, or mental health treatment. The American Academy of Family Physicians follows USPSTF guidelines for screening all adult patients for depression, using the clinician's choice of screening method (19) . The US Department of Veterans Affairs (VA) recommends annual depression screening for adult patients in primary care but notes the USPSTF recommendation of screening only when staff-assisted supports are in place (18) . The American College of Obstetricians and Gynecologists (ACOG) does not advocate for or against screening for depression during well-woman care, but states that when clinicians identify a woman with depression, they must provide follow-up care if they do not refer her for care elsewhere (16) . The American Academy of Pediatrics (AAP) recommends screening mothers for depression at the 1-, 2-, 4-and 6-month well-child visits and beyond the postpartum period (20) . The American Psychiatric Association has no published guidelines specific to depression screening, but in its guidelines on treatment for major depressive disorder, it acknowledges that primary care physicians, obstetricians, and physicians of other disciplines may screen for depression and initiate treatment for patients (21) . The USPSTF, VA, ACOG, and AAP mention the 2-item Patient Health Questionnaire (PHQ-2), as an example of a short, standardized screener for depression.
Question 2. What are the prevalence and predictors of screening?
We did not find any studies that assessed prevalence and predictors among nonpregnant women of reproductive age only. Four individual studies reported on prevalence rates of screening for depression among adult women of any age in primary care settings (22, 23) or by providers serving women of reproductive age in obstetric practices (24,25). Desai et al evaluated the VA experience in implementing universal screening, using a validated instrument, for depression (22) . This study included 21,000 people receiving care at VA facilities across the United States in 2002. More than 84% of women of any age and almost 80% of women and men aged 45 or younger were screened for depression. Among patients of all ages, no difference was found in screening rates between women and men, but patients were less likely to be screened if they were younger, unmarried, had greater service disability, or had medical comorbidity. reported routinely asking about depression or using a screening questionnaire to identify major or minor depression. The most common reasons for recognition of depression by OB/GYNs were that the patient appeared distressed (38%), presented with a symptom (34%), or introduced the topic directly (26%).
Question 3. How well do screening tools detect depression?
We did not find any studies that assessed performance of depression screening tools among nonpregnant women of reproductive age only. Several short (1-2 questions) and longer (up to 30 questions) validated tools are available to screen for depression in primary care populations (26,27). The PHQ-2, which asks, "Over the past 2 weeks, how often have you been bothered by a) little interest or pleasure in doing things and b) feeling down, depressed, or hopeless," may perform as well as longer tools (28) or could be used as an initial screen, with a longer screen administered to patients with affirmative answers to both questions (18) . Depression-specific instruments may help clinicians recognize depression more easily than instruments that measure multiple mental health conditions (29) . With any screening tool, a diagnostic interview is needed to confirm the presence of depression.
We found 1 meta-analysis of the performance of instruments among adult men and women in primary care settings (30). It examined performance of case-finding instruments used for routine screening in primary care populations of men and women of all ages (30). This article evaluated only 21 of the 38 studies identified (because of study limitations); the 21 studies examined 16 validated case-finding instruments. For detecting major depression in a primary care population using routine screening with a validated case-finding tool, the median sensitivity was 85% (range, 50%-97%), the median specificity was 74% (range, 51%-98%), and no statistically significant differences between instruments were found. The study concluded that several case-finding instruments are feasible to use in primary care settings and that the instruments perform sufficiently to facilitate identification of depression.
Question 4. Does screening lead to diagnosis, treatment, and improved outcomes?
We did not find any systematic reviews or individual studies that addressed this question among nonpregnant women of reproductive age only. We found 2 metaanalyses (29,31) and 1 systematic review (32) that examined this question among the general population in primary care and hospital settings. Two studies (31,32) were conducted to inform and update USPSTF guidelines on screening for depression in adults. Pignone et al reviewed randomized trials published between January 1994 and August 2001 and included 14 studies in primary care settings that examined the effect of screening patients for depression on identification, treatment, and health outcomes (31). The included trials examined a range of screening intervention strategies, including feedback of screening scores, feedback and general education of providers, feedback and treatment advice, and integrated recognition and management approaches with coordinated follow-up of diagnosis and treatment. Screening resulted in a 2-to 3-fold increase in clinicians' recognition of depression. However, in a comparison of absolute differences in proportions treated, the effect of screening on rates of treatment was mixed; 4 studies found positive effects and 5 studies found no effect. Increases in rates of treatment generally resulted in increases in prescriptions for antidepressants rather than referrals to mental health professionals. Three out of 7 studies included in the meta-analysis found significant improvement in depression between groups screened for depression and groups not screened. The meta-analysis found that patient and provider characteristics, use of particular outcome measures, follow-up time, or trial quality In pooled data from 5 studies that examined the effect of screening on depression outcomes, the meta-analysis found no effect (standardized mean difference, −0.02; 95% CI, −0.25 to 0.20) (29). The authors conclude that use of screening instruments alone in unselected populations within primary care and hospital settings, without organizational enhancements, does not improve rates of depression treatment or outcomes. They state that routine screening among high-risk populations may be more effective.
Question 5. What are the most effective treatment methods
We found 5 meta-analyses and no individual studies that met the inclusion criteria for nonpharmacologic treatments and 3 post-hoc analyses of pooled data that examined the effectiveness and safety of SSRIs and SNRIs in women.
Three meta-analyses explored the association between exercise and depression and evaluated differences by sex (33-35) ( Psychotherapy resulted in lower mean depression scores compared with no treatment (ES = 0.93). No differences were found by sex. Gloaguen et al (36) conducted a metaanalysis of 48 RCTs to evaluate the effectiveness of CT for treatment of major depression or dysthymic disorder. They found that CT was more effective than antidepressants, and there were no differences by sex.
Three articles examined the effectiveness and safety of SSRIs and SNRIs in women, and all were post-hoc analyses of pooled data ( Meets criteria for inclusion in the National Guideline Clearinghouse (http:// www.guideline.gov/about/inclusion-criteria.aspx)
Additional requirements included:
• Was developed by a national organization.
• Provides detailed information about the methods used to search, collect, and select the evidence (either in the original guideline, or in an associated evidence review).
• Provides details about the methods used to assess the quality of the literature (eg, either rating or grading the literature that the recommendations are based on, providing evidence tables and detailed discussion of the underlying evidence).
• Makes clear recommendations.
• Includes the target population. Specific reference to the target population is not necessary to meet this inclusion criterion. For example, guidelines for the general adult populations would be included as they are assumed to be relevant to the target population (women of reproductive age who are not pregnant).
Adult men and women (guidelines)
What are the prevalence and predictors of screening?
Describes a study that screened patients for depression or a survey of clinicians' reports or medical record review of screening for depression.
Adult women and women seen by obstetrician/gynecologists (individual studies)
How well do screening tools detect depression? b
Describes a validated screening tool for depression in adult primary care populations.
Adult men and women 1 (meta-analysis)
Does screening lead to diagnosis, treatment, and improved outcomes? b
Presents data related to the rates of depression diagnosis and treatment among patients screened for depression compared with patients not screened.
Adult men and women (2 meta-analyses, 1 systematic review)
What are the most effective treatment methods?
Examines the effect of exercise, psychotherapy, SSRI, or SNRI c on depression.
Adult men and women from the general population with results presented separately for women, or gender evaluated as an effect modifier 8 ( meta-analyses, post-hoc analyses of pooled data)
Abbreviations: SSRI, selective serotonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor. a All studies and reports were full-length articles published in the English language, between 10 and 2010. b Given the lack of studies reporting data separately for women, articles for the general US population were included. American Academy of Pediatrics, 2010 (20) Recommends screening mothers for depression at the 1-, 2-, -, and 6-month well-child visits and beyond the postpartum period. Based on the severity of the depression score, pediatricians should provide reassurance, supportive strategies, and referral for specific interventions.
Edinburgh Postnatal Depression Scale for postpartum depression and PHQ-2 to assess depression outside of the postpartum period. Outcome: Level of depression; intervention: aerobic and resistance exercise; comparison groups: no treatment, wait-list, psychotherapy, enjoyable activity, relaxation, less exercise, anaerobic exercise, exercise and psychotherapy; covariates: source of subjects, group assignment, degree of internal validity, initial level of depression, age, sex, exercise duration per episode, type, frequency and intensity, additional therapy, health status.
Results
The overall ES a of exercise on depression was −0.53 ± 0.85. Significant main effects were found for source of subjects (medical/psychological patients > students/citizens); source of study (published > unpublished); purpose of exercise (medical rehabilitation > general health or psychological rehabilitation); health status (sicker > healthier); type of exercise (weight training > aerobic); duration (longer > shorter). No significant moderating effects found for group assignment, internal validity, sex, age, or depression diagnosis.
Limitations
Included non-RCT studies and studies with depression as secondary diagnosis to another mental health condition. Population of interest and exclusion criteria 2,18 people with depression as primary diagnosis or secondary diagnosis to another mental health condition; excludes studies on depression as a result of physical health problem.
Outcome, intervention, comparison group, and covariates Outcome: level of depression; intervention: aerobic and resistance exercise; comparison groups: wait-list, group or individual therapy, behavioral interventions; covariates: initial level of depression; age; sex; exercise duration per episode, type, frequency, and intensity; additional therapy.
Results
Compared with wait-list controls, people who exercised were ES 0.77 (95% CI, −1.08 to −0.47) less depressed than individuals on a wait list. Exercise was as beneficial as group/individual therapy and behavioral interventions. Significant main effects were found for initial level of depression (moderate to severe group > mild to moderate group); source of study (published > unpublished); primary versus secondary depression; no significant moderating effects were found for sex , age, or exercise type, duration, frequency, or intensity on the relationship between exercise and depression. Individuals who exercised 9-12 weeks were less depressed than those who exercised ≤8 weeks.
Limitations
Included non-RCT studies; included depression as secondary diagnosis to another mental health condition; limited generalizability because of exclusion criteria; measures of level of depression not stated. 
Population of interest and exclusion criteria
People with depression either meeting formal diagnostic criteria or screening positive; excluded subjects described in more general terms or by other specific diagnoses; studies examining inpatients or children and adolescents also excluded; mean age: years, range: 1-1
Outcome, intervention, comparison group, and covariates Outcome: depression symptoms; assessed by multiple different validated screeners for depression, general mental health and functioning; intervention: 1 of types of therapies: 1) cognitive, 2) behavioral, ) cognitive-behavioral, ) general verbal, mean weeks of treatment and 8. mean number of sessions; comparison: no treatment (n = 6 studies), wait list (n = 2 studies), placebo (n = studies); covariates: sex and age, weeks of treatment, number of sessions.
Results
Psychotherapy was more effective than no treatment (ES = 0. at posttreatment and 0.68 at follow-up, average 1 weeks after treatment) and wait list (ES = 0.8) (P < .0 for all). In the 2 studies using outcome measures specific to depression, psychotherapy was more effective than wait list (ES = 0., P < .0). No differences in effect sizes found by sex, age, weeks of treatment, or number of sessions.
Limitations
Included non-RCTs; limited to published articles and abstracts presented at conferences. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
SSRIs/SNRIs
Treatment Description
SSRIs/SNRIs (continued)
Results
For both men and women, both venlaflaxine and SSRIs were significantly more effective in depression absence, response, and remission than placebo. At 8 weeks, rates of remission among women treated with venlaflaxine were higher (%) than those among people receiving SSRIs (%) or placebo (2%), P < .001. Rates of response with venlaflaxine (6%) were higher than placebo (%), P < .001. Rates of absence of depressed mood among women receiving venlaflaxine (%) or SSRI (1%) were higher than placebo (20%), P < .003. Among participants ≤40 years (men and women combined), rates of remission (P < .001) and absence of depression (P < .001) were higher with venlafaxine than placebo. Differences between SSRIs and placebo were not statistically significant among participants ≤40 years. Population of interest and exclusion criteria 2 people with depression; 1 (%) women with depression; n = 80 on placebo; n = 1 on SSRI; n = 26 on SNRI; excluded people with severe illness, suicidal patients, and patients with concomitant disorders.
Outcome, intervention, comparison group and covariates
Outcome: level of depression assessed by response and remission rates from HAM-D-1 scores; intervention: SSRI (fluoxetine, paraxetine CR, sertaline, citalopram, excitalopram), SNRI (venlaflaxine ER); comparison group: placebo; covariates: baseline depression score and sex.
Response rates greater for women taking SSRIs (6.8%) and SNRIs (6.2%) than placebo (0%) (P < .001).
Remission rates higher in women taking SSRIs (.1%) and SNRIs (6.2%), than placebo (1.8%) (P < .001). Women taking SSRIs had ES 0.82, and women taking SNRI had ES 0. Population of interest and exclusion criteria N = 1622 people with major depressive disorder defined as HAM-D-1 score >1; 1,062 women n = 8 duloxetine; n = 8 placebo; mean age 1 years; excluded people with current and primary Axis I disorder other than depression, an Axis II disorder, lack of response to ≥2 courses of antidepressant therapy, serious medical illness, risk of suicide, history of substance abuse in last year, positive drug screen.
Outcome: level of depression; intervention: duloxetine (0, 60, 80, and 120 mg/day); comparison group: placebo; covariates: sex, study design characteristics, methodological characteristics, study duration (-weeks).
Abbreviations: RCT, randomized controlled trial; ES, effect size; CI, confidence interval; BDI, Beck Depression Inventory; NR, not reported; SSRI, selective serotonin reuptake inhibitor; SNRI, selective norepinephrine reuptake inhibitor; HAM-D, Hamilton Rating Scale for Depression; CGIS, Clinical Global ImpressionsSeverity; PGI-I, Patient Global Impression of Improvement scale; VAS, visual analogue scale. a ES = standardized mean difference between intervention and control groups. 
